UK: Lab Tools Fluidic Analytics Set to Unlock Biology Behind Major Diseases
Fluidic Analytics has raised $ 31 million to continue developing its transformational products for characterising proteins and their behaviour. The proceeds of the financing will be used to continue the commercial roll-out of the company’s lab-tools pipeline and to develop further high-value clinical applications of its technology.
Cambridge/UK — Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the right time. DNA gives clues about what is likely to happen over a lifetime. Proteins and their behaviour tell us what is actually happening now. To date, the emergence of a deep understanding of the biology underlying disease and health in real time has been hampered by the shortcomings of existing tools for protein characterisation.
The company’s products are based on a proprietary technology platform from the University of Cambridge. This platform was designed explicitly to give deep insights into the way that proteins fold, aggregate and interact by characterising them in solution — precisely as they exist in the body. These products have the potential to help researchers understand the mechanisms underlying conditions like Alzheimer’s disease, pharmaceutical companies develop more effective drugs, and patients gain access to more accurate diagnostics in the clinic, at the pharmacy or even at home.
The financing was led by Draper Esprit, a pan-European venture capital fund that invests in disruptive technology companies at the early and growth stages. Joining the round as new investors were Delin Ventures and BGF, making its largest life-sciences investment to date and first in Cambridge. IQ Capital and Amadeus Capital Partners also joined Draper Esprit in backing Fluidic Analytics for a third successive time since the company’s first financing in 2015.
According to Andrew Lynn, Chief Executive Officer, Fluidic Analytics, this financing will power the global commercial launch of the company's Fluidity One system and enable them to bring the next two lab-tools products to market. It would also allow them to advance a number of high-potential clinical applications, he added.